Telomere biology and telomere diseases: implications for practice and research.
The recent recognition of genetic defects in telomeres and telomere repair in multiple human diseases has practical implications for hematologists and oncologists and their patients; consequences for future clinical research in hematology and other subspecialties; and even importance in the interpretation of animal experiments involving cell propagation. Telomere diseases include constitutional marrow failure as dyskeratosis congenita, some apparently acquired aplastic anemia, myelodysplasia and acute myeloid leukemia; pulmonary fibrosis; and hepatic nodular regenerative hyperplasia and cirrhosis. Accelerated telomere attrition is a likely pathophysiology of cancer arising from chronic inflammation. Telomerase can be modulated by sex hormones, which may explain the activity of androgens in marrow failure. Measurement of telomere length of peripheral blood leukocytes is a simple screening clinical assay. Detection of a mutation in a patient has implications for therapy, prognosis, monitoring, and genetic counseling. For research in hematology and oncology, telomere biology could be assessed as a risk for secondary malignancies and in graft-versus-host disease, for progression in a variety of blood cancers, and as potentially modifiable by hormone replacement strategies.
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA. youngns@mail.nih.gov
Neal S
NS
Young
D000818:Animals; D035843:Biomedical Research; D004194:Disease / Q000235:genetics*; D006801:Humans; D008511:Medicine; D009369:Neoplasms / Q000235:genetics; D016615:Telomere / Q000378:metabolism*
J Med Genet. 2008 Oct;45(10):654-6
18835860
Lancet. 2003 Nov 15;362(9396):1628-30
14630445
Nat Genet. 1998 May;19(1):32-8
9590285
Blood. 2009 Sep 10;114(11):2236-43
19561322
Nature. 2001 Sep 27;413(6854):432-5
11574891
Leukemia. 1998 Jan;12(1):13-24
9436916
Blood. 2001 Feb 15;97(4):895-900
11159514
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7552-7
17460043
Br J Haematol. 2000 Sep;110(4):768-79
11054058
PLoS One. 2009 Nov 20;4(11):e7926
19936245
Cancer Sci. 2008 Aug;99(8):1528-38
18754863
N Engl J Med. 2005 Apr 7;352(14):1413-24
15814878
Nat Med. 2006 Oct;12(10):1133-8
17024208
Cell. 2001 Aug 10;106(3):275-86
11509177
Nat Rev Immunol. 2002 Sep;2(9):699-706
12209138
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9857-60
7937905
Blood. 2009 Jul 2;114(1):219-22
19411630
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15960-4
16247010
Nature. 2000 Aug 10;406(6796):641-5
10949306
JAMA. 2010 Sep 22;304(12):1358-64
20858879
Hum Mutat. 2009 Nov;30(11):1567-73
19760749
Blood. 2007 Sep 1;110(5):1439-47
17468339
Nature. 1999 Dec 2;402(6761):551-5
10591218
Cold Spring Harb Symp Quant Biol. 2005;70:197-204
16869754
Nat Genet. 2002 Oct;32(2):280-4
12355086
Hum Mol Genet. 2007 Jul 1;16(13):1619-29
17507419
Cancer Res. 1994 Jul 1;54(13):3557-60
8012981
Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8073-8
18523010
Blood. 2009 Jun 25;113(26):6549-57
19282459
Genes Chromosomes Cancer. 2006 Mar;45(3):247-56
16281260
Am J Hum Genet. 2008 Feb;82(2):501-9
18252230
Leuk Res. 2004 Oct;28(10):1013-21
15289012
N Engl J Med. 2007 Mar 29;356(13):1317-26
17392301
J Clin Oncol. 2009 Feb 10;27(5):791-8
19124806
Blood. 1998 May 15;91(10):3582-92
9572992
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1187-92
19147845
N Engl J Med. 2009 Dec 10;361(24):2353-65
20007561
Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55
18086770